May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Avastin Enhancement and Macugen Maintenance Therapy for Exudative Age Related Macular Degeneration
Author Affiliations & Notes
  • M.J. Tolentino
    Center For Retina And Macular Disease, Winter Haven, FL
  • D.M. Misch
    Center For Retina And Macular Disease, Winter Haven, FL
  • A.S. Berger
    Center For Retina And Macular Disease, Winter Haven, FL
  • S.J. Moon
    Center For Retina And Macular Disease, Winter Haven, FL
  • Footnotes
    Commercial Relationships  M.J. Tolentino, Eyetech, R; Pfizer, I; Pfizer, C; Eyetech, C; Pfizer, R; D.M. Misch, None; A.S. Berger, None; S.J. Moon, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5912. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.J. Tolentino, D.M. Misch, A.S. Berger, S.J. Moon; Avastin Enhancement and Macugen Maintenance Therapy for Exudative Age Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5912.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Pegaptanib Sodium (Macugen) is a VEGF 165 selective inhibitor that has been shown to be efficacious and safe for the treatment of exudative AMD. Bevacizumab (Avastin) is a pan Vascular Endothelial Growth Factor (VEGF) isoform inhibitor that is approved for intravenous use for cancer and is under investigation as an intravitreal drug for the treatment of ocular neovascular disorders. The purpose of this study is to determine if supplemental administration of intravitreal Avastin can enhance the clinical efficacy of intravitreal Macugen and to determine if Macugen can maintain any gain in vision obtained from Avastin injection.

Methods: : Eight eyes of 8 patients who received one or more prior intravitreal injections of Macugen for exudative age related macular degeneration were given a supplemental injection of Avastin 1–4 weeks after an injection of Macugen. Snellen visual acuity and optical coherence tomography were measured prior to, 1 week after Avastin injection and immediately before subsequent Macugen injections.

Results: : 1/8 (12.5%) patients developed a worsening of vision, 4/8 (50%) maintained the same vision and 3/8 (37.5%) of patients had an improvement of 1 or more lines of visual acuity. These results were seen 1 week post Avastin injection and results remain stable with subsequent injections of Macugen.

Conclusions: : These preliminary results suggest Avastin has the potential to improve vision in patients who have received previous Macugen and that Macugen can be used to maintain these gains. The use of Avastin as a "booster shot" in conjunction with Macugen could potentially minimize the potential toxicity of a pan isoform VEGF inhibitor (Avastin) while taking advantage of the safety profile of a VEGF 165 selective inhibitor ( Macugen)

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×